Management of Pancreatic Mass Without Histopathologic Diagnosis

Initial Assessment and Staging

The American Gastroenterological Association recommends obtaining contrast-enhanced multiphasic CT or MRI with a defined pancreas protocol to assess tumor size, vascular involvement, and metastatic disease 1, 2, 4
The National Comprehensive Cancer Network suggests performing chest CT to evaluate for pulmonary metastases 4
Consider EUS for complementary staging information, particularly for assessing vascular invasion and lymph node involvement, as recommended by the American College of Gastroenterology 4
Laparoscopy with laparoscopic ultrasound may be appropriate in selected cases to rule out occult peritoneal metastases, especially for body and tail lesions, according to the European Society for Medical Oncology 1, 2, 4

For potentially resectable lesions, proceed directly to surgical resection without preoperative tissue diagnosis if the patient is a good surgical candidate, as recommended by the American College of Surgeons 1, 2, 3
The American Society of Clinical Oncology recommends obtaining tissue diagnosis before initiating treatment for borderline resectable or unresectable lesions, with EUS-guided FNA as the preferred method 5, 3
The diagnostic sensitivity of EUS-guided FNA for pancreatic masses is 70-85%, according to the American Gastroenterological Association 5

Resections should be performed at high-volume centers (15-20 pancreatic resections annually), as recommended by the American College of Surgeons 4
Multidisciplinary consultation should guide decisions about resectability and management, according to the National Comprehensive Cancer Network 4
If obstructive jaundice is present, endoscopic plastic stent placement is preferred over transhepatic stenting, as recommended by the American College of Gastroenterology 1, 4